918²«ÌìÌÃ

¡°±£ÎÀÉöÖ°ÄÜ¡ªIgAÉöÓѰٳǹ«ÒæÐÓ×±³¤É³Õ¾ÔÚ918²«ÌìÌôóÒ©·¿Îåһ·µê³É¹¦½øÐÐ

918²«ÌìÌÃ(Öйú)ÈËÉú¾ÍÊDz«
IgAÉö²¡ÊÇÈ«ÇòÁìÓòÄÚ×î³£¼ûµÄÔ­·¢ÐÔÉöÓ×Çò¼²²¡Ö®Ò»£¬£¬ £¬ £¬£¬£¬£¬£¬ÔÚÎÒ¹ú¼°¶«Ñǹú¶ÈÓÈΪ³£¼û¡£¡£¡£¡£¡£´óÎÞÊý»¼Õß²û·¢ÎªÉöÔಡ»ºÂý½øÕ¹£¬£¬ £¬ £¬£¬£¬£¬£¬Êǵ¼ÖÂÇàÄêÈËÖÕδÆÚÉö²¡µÄ×î³£¼û²¡Òò£¬£¬ £¬ £¬£¬£¬£¬£¬¸ø¼ÒÍ¥ºÍÉç»á´øÀ´Á˳Á³ÁµÄ¼²²¡Ö°ÊØ¡¾1¡¿¡£¡£¡£¡£¡£ÔÚIgAÉö²¡µÄÒ½Öιý³ÌÖУ¬£¬ £¬ £¬£¬£¬£¬£¬»¼Õß½ÌÓýÊdzÁÒª»·½Ú£¬£¬ £¬ £¬£¬£¬£¬£¬¶øÄ¿Ç°IgAÉö²¡»¼Õߵļ²²¡ÈÏÖª¡¢×ÔÎÒÖÎÀíÄÜÁ¦ÈÔÓнϴóÌáÉý¿Õ¼äºÍδÂú×ãÐèÒª¡£¡£¡£¡£¡£
ΪÁËÔ®ÊÖ¸ü¶àIgAÉö²¡»¼Õß»ñÈ¡ÕïÁÆÖªÊ¶¡¢Ìá¸ß¼²²¡ÖÎÀíÄÜÁ¦£¬£¬ £¬ £¬£¬£¬£¬£¬¡°±£ÎÀÉöÖ°ÄÜ¡ªIgAÉöÓѰٳǹ«ÒæÐÓ×±ÏîÄ¿³¤É³Õ¾»î¶¯ÔÚ918²«ÌìÌôóÒ©·¿Îåһ·µê½øÐУ¬£¬ £¬ £¬£¬£¬£¬£¬Í¨¹ýÏßÉÏÏßÏÂÏà½áºÏµÄÉöÓѽÌÓý»î¶¯¡¢Ò½»¼»¥¶¯¼°¿ÆÆÕ´«²¼£¬£¬ £¬ £¬£¬£¬£¬£¬Íƶ¯»¼ÕßÔçÕïÔçÖΣ¬£¬ £¬ £¬£¬£¬£¬£¬´Ó¶øÑÓ»º¼²²¡½øÕ¹£¬£¬ £¬ £¬£¬£¬£¬£¬Ìá¸ßÉúÑÄÖÊÁ¿¡£¡£¡£¡£¡£
918²«ÌìÌÃ(Öйú)ÈËÉú¾ÍÊDz«
³¤É³ÊÐÉö´È¹«Òæ·þÎñÖÐÉúÀíʳ¤ºî¼ÑÏÖ³¡Ö´ǣ¬£¬ £¬ £¬£¬£¬£¬£¬·ÖÏí¹«ÒæÁ¦Á¿ÔÚÉö²¡Ôçɸ¡¢»¼Õß½ÌÓý¼°ÉúÀíÖ§³ÖµÈ·½ÃæµÄʵ¼Ê¾­Ñé¡£¡£¡£¡£¡£
±¾´Î»î¶¯Ô¼ÇëÁËÖÐÄÏ´óÑ§ÏæÑÅÈýÒ½ÔºÉöÄÚ¿ÆÁõ¼Íʵ½ÌÊÚ´øÀ´Ö÷Ìâ½²×ù£¬£¬ £¬ £¬£¬£¬£¬£¬ÒÔÕæÊµ°¸Àý½â˵IgAÉö²¡µÄ·¢²¡²û·¢¡¢ÉúÑÄÒûʳ׼Ôò¡¢IgAÉö²¡Ò©ÎïÕïÁƹ滮µÈ֪ʶ£¬£¬ £¬ £¬£¬£¬£¬£¬¼¤Àø¸÷ÈËÕýÈ·Òâʶ¼²²¡£¡£¡£¡£¡£¬£¬ £¬ £¬£¬£¬£¬£¬×öµ½ÔçÕï¡¢ÔçÖΡ¢Ôç°²ÐÄ¡£¡£¡£¡£¡£
918²«ÌìÌÃ(Öйú)ÈËÉú¾ÍÊDz«
ÔÚÏÖ³¡´ðÒÉ»·½Ú£¬£¬ £¬ £¬£¬£¬£¬£¬Áõ¼Íʵ½ÌÊÚÕë¶Ô»¼Õß¹ØÇеÄÎÊÌâÖðÒ»½â´ð¡£¡£¡£¡£¡£¹ØÓںöàÉöÓѹØÇеIJ¼µØÄ峦ÈܽºÄÒµÄÎÊÌ⣬£¬ £¬ £¬£¬£¬£¬£¬Áõ½ÌÊÚ½â´ð£º²¼µØÄ峦ÈܽºÄÒ£¨Ä͸³¿µ?NEFECON?£©ÊÇÈ«ÇòÊ׸ö°ÐÏòIgAÉö²¡Ô´Í·–³¦Â·ð¤Ä¤ÃâÒߵĶÔÒòÒ½ÖÎÐÂÒ©£¬£¬ £¬ £¬£¬£¬£¬£¬ÊÇÊ׸öͬʱ±»ÃÀ¹úFDA¡¢Å·ÖÞEMA¡¢ÖйúNMPAÈý´óȨÍþÒ©¼à»ú¹¹ºË×¼ÓÃÓÚÒ½ÖÎIgAÉö²¡µÄ´´ÐÂÒ©Î2-7¡¿£¬£¬ £¬ £¬£¬£¬£¬£¬ÓµÓгÁ´óÁÙ´²Òâ˼¡£¡£¡£¡£¡£ËüºÏÓÃÓÚÓµÓнøÕ¹·çÏÕµÄÔ­·¢ÐÔIgAÉö²¡³ÉÄ껼Õߣ¬£¬ £¬ £¬£¬£¬£¬£¬Äܹ»Ï÷¼õÉöÖ°ÄÜʧÂ䣬£¬ £¬ £¬£¬£¬£¬£¬Í¬Ê±½µµÍµ°°×Äò¡¢¸ÄÉÆÑªÄò¡£¡£¡£¡£¡£
²¼µØÄ峦ÈܽºÄÒ£¨Ä͸³¿µ?NEFECON?£©ÔÚ918²«ÌìÌôóÒ©·¿ÓÐÊÛ£¬£¬ £¬ £¬£¬£¬£¬£¬ÎÒÃÇ»ý¼«¹²Í¬ÁÙ´²ÐèÒª£¬£¬ £¬ £¬£¬£¬£¬£¬ÊµÊ±ÎÈÍ׵ؽ«Ò©Æ·ÅäË͵½»¼Õß±ØÒªµÄ´¦Ëù¡£¡£¡£¡£¡£
918²«ÌìÌò¿ÃÅDTPÒ©·¿ÐÅÏ¢Ò»ÀÀ£º
918²«ÌìÌÃ(Öйú)ÈËÉú¾ÍÊDz«
²Î¿¼Îļþ£º

1.ÐÂÒ©ÀûÓúÍÒ½ÖÎÕ½Êõת±äÓÐÍû¸ÄÉÆIgAÉö²¡»¼ÕßµÄÔ¤ºó[J]. ÖлªÒ½Ñ§ÐÅÏ¢µ¼±¨,2024,39(16):11. DOI:10.3760/cma.j.issn.1000-8039.2024.16.118.
2.https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20231124144653113.html.
3.FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease
4.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo--for-adults-with-primary-iga-nephropathy,c3600434.
5.https://www.calliditas.se/en/calliditas-therapeutics-announces-full-fda-approval-of-tarpeyo-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-reduce-the-loss-of-kidney-function/
6.https://www.everestmedicines.com/zhhans/news/yundingxinyaohezuohuobancalliditasxuanbunaifukanghuodemeiguofdawanquanpizhunyongyuzhiliaoyoujinzhanfengxiandeigashenbinghuanzhe-wulunqijixiandanbainiaoshuiping/936f18ac-566a-4b3d-8cd0-036f720b62e6/
7.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo--for-adults-with-primary-iga-nephropathy,c3600434.
ÉÏһƪÎÄÕÂ
918²«ÌìÌóÁ°õÐÂÆ·ÁÁÏàÕÑͨҩ½»»á£¬£¬ £¬ £¬£¬£¬£¬£¬ÏÖ³¡Ç©Ô¼Æô·¢¹úÄÚ±íÊг¡
ÏÂһƪÎÄÕÂ
¿ÆÑ§°ÍÊ¿¿ª½ø918²«ÌìÌ㬣¬ £¬ £¬£¬£¬£¬£¬´ò¿¨ÖÐÒ½Ò©¿Æ¼¼ÎÄ»¯ºþÄÏÊ¡¿ÆÆÕ»ùµØ
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿